The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Clinical and Immunologic Characteristics of Melanoma-Associated Retinopathy Syndrome: Eleven New Cases and a Review of 51 Previously Published Cases
Abstract
OBJECTIVE: To evaluate the signs, symptoms, and immune responses of patients with melanoma-associated retinopathy (MAR) syndrome. MATERIALS AND METHODS: We reviewed the clinical and immunologic findings of 62 MAR syndrome patients. They include 25 patients from our institution (11 not previously reported) and 37 patients reported from other institutions. RESULTS: There were 33 men and seven women (no gender information is available for the remaining 22 cases). Age at onset of the visual disturbance averaged 57.5 years (range, 30-78). Visual acuity of 20/60 or better was initially present in 82%. Fundus examination was normal in 44%, optic disc pallor was present in 23%, and retinal vessel attenuation was present in 30%. Vitreous cells were present in 30%. The latency from melanoma diagnosis to recognition of MAR syndrome averaged 3.6 years (range, 2 months to 19 years). Seven patients sustained visual improvement with various treatment regimens, especially with intravenous immunoglobulin and cytoreductive surgery (metastasectomy). Indirect immunohistochemical staining of the bipolar layer was typical, but several other retinal elements were also reactive. Tissue from a metastatic melanoma excised from one of the patients expressed antigens that reacted with antiretinal antibodies. CONCLUSION: MAR syndrome demonstrates diverse clinical and immunologic features. Treatment, especially intravenous immunoglobulin and cytoreductive surgery (metastasectomy), improves vision in some cases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862
Chang, A. E., Karnell, L. H., & Menck, H. R. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981015)83:8<1664::aid-cncr23>3.0.co;2-g · Cited by 1,663
Livingston, P. O., Wong, G. Y., Adluri, S., Tao, Y., Padavan, M., Parente, R., Hanlon, C., Calves, M. J., Helling, F., & Ritter, G. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.5.1036 · Cited by 516
Molecular Mimicry and Autoimmunity
Albert, L. J., & Inman, R. D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912303412707 · Cited by 516
Dendritic Cell Vaccines for Cancer Immunotherapy
Timmerman, M., & Levy, M. (1999) · Annual Review of Medicine · doi:10.1146/annurev.med.50.1.507 · Cited by 485
Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma
Mastrangelo, M. J., Maguire, H. C., Eisenlohr, L. C., Laughlin, C. E., Monken, C. E., McCue, P. A., Kovatich, A. J., & Lattime, E. C. (1999) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700066 · Cited by 353
Multifocal motor neuropathy improved by IVIg: Randomized, double-blind, placebo-controlled study
Federico, P., Zochodne, D. W., Hahn, A. F., Brown, W. F., & Feasby, T. E. (2000) · Neurology · doi:10.1212/wnl.55.9.1256 · Cited by 263
Thirkill, C. E., FitzGerald, P., Sergott, R. C., Roth, A. M., Tyler, N. K., & Keltner, J. L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912073212307 · Cited by 242
Self-citationReversal of Tumor-Induced Immunosuppression: A New Approach to Cancer Therapy
Wojtowicz-Praga, S. (1997) · Journal of Immunotherapy · doi:10.1097/00002371-199705000-00001 · Cited by 240
The cancer-associated retinopathy antigen is a recoverin-like protein.
Thirkill, C. E., Tait, R. C., Tyler, N. K., Roth, A. M., & Keltner, J. L. (1992) · PubMed · Cited by 236
Self-citation
Cited by
Connelly‐Smith, L., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 684
Paraneoplastic neurological syndromes
Honnorat, J., & Antoine, J.-C. (2007) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-2-22 · Cited by 357
Williams, T. J., Benavides, D. R., Patrice, K.-A., Dalmau, J. O., de Ávila, A. L. R., Le, D. T., Lipson, E. J., Probasco, J. C., & Mowry, E. M. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.1399 · Cited by 276
Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy
Adamus, G., Ren, G., & Weleber, R. G. (2004) · BMC Ophthalmology · doi:10.1186/1471-2415-4-5 · Cited by 254
MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects
Urner-Bloch, U., Urner, M., Jaberg-Bentele, N., Frauchiger, A. L., Dummer, R., & Goldinger, S. M. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.018 · Cited by 82
Metadata
- Authors
- Keltner, J. L., Thirkill, C. E., & Yip, P. T.
- Venue
- Journal of Neuro-Ophthalmology
- Published
- 2001-09
- Volume
- 21
- Issue
- 3
- Pages
- 173-187
- ISSN
- 1070-8022 (ISSN-L)
- OpenAlex
- W2061952603
- Cited by
- 258
- References
- 31
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical and Immunologic Characteristics of Melanoma-Associated Retinopathy Syndrome: Eleven New Cases and a Review of 51 Previously Published Cases. https://app.cochat.ai/papers/10.1097/00041327-200109000-00004
- The paper
- Keltner, J. L., Thirkill, C. E., & Yip, P. T. (2001). Clinical and Immunologic Characteristics of Melanoma-Associated Retinopathy Syndrome: Eleven New Cases and a Review of 51 Previously Published Cases. Journal of Neuro-Ophthalmology. https://doi.org/10.1097/00041327-200109000-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.